Alx Oncology's evorpacept in combination with zanidatamab generates promising, durable response in patients with advanced her2-positive breast cancer and high cd47 expression

Published: 2026-05-07 08:21:25 ET ALXO

Published on 05/07/2026 at 08:21 am EDT